Dorman, K., Boeck, S., Caca, K., Reichert, M., Ettrich, T. J., Oettle, H., . . . Kullmann, F. (2024). Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): A multicentre, randomised, open-label, phase 2 trial. The lancet. Gastroenterology & Hepatology, 9(10), . https://doi.org/10.1016/S2468-1253(24)00197-3
Chicago-Zitierstil (17. Ausg.)Dorman, Klara, et al. "Alternating Gemcitabine Plus Nab-paclitaxel and Gemcitabine Alone Versus Continuous Gemcitabine Plus Nab-paclitaxel After Induction Treatment of Metastatic Pancreatic Cancer (ALPACA): A Multicentre, Randomised, Open-label, Phase 2 Trial." The Lancet. Gastroenterology & Hepatology 9, no. 10 (2024). https://doi.org/10.1016/S2468-1253(24)00197-3.
MLA-Zitierstil (9. Ausg.)Dorman, Klara, et al. "Alternating Gemcitabine Plus Nab-paclitaxel and Gemcitabine Alone Versus Continuous Gemcitabine Plus Nab-paclitaxel After Induction Treatment of Metastatic Pancreatic Cancer (ALPACA): A Multicentre, Randomised, Open-label, Phase 2 Trial." The Lancet. Gastroenterology & Hepatology, vol. 9, no. 10, 2024, https://doi.org/10.1016/S2468-1253(24)00197-3.